Publications by authors named "Christopher Hawkes"

Claim this Profile
V
Validity of model for predicting risk of relapse in MOGAD.
Mulan Jiang, Philippe Antoine Bilodeau, Brian Healy, E Ann Yeh, Gavin Giovannoni, Christopher Hawkes

Mult Scler Relat Disord· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When does multiple sclerosis start?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of First and Subsequent Attacks in Multiple Sclerosis.
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental health as an unmet medical need in NMOSD: how can we do better?
C Virginia O'Hayer, Ann Yeh, Christopher Hawkes, Jeannette Lechner-Scott, Gavin Giovannoni

Mult Scler Relat Disord· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin D- should we all take it?
Jeannette Lechner-Scott, E Ann Yeh, Christopher Hawkes, Gavin Giovannoni, Michael Levy

Mult Scler Relat Disord· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IS MULTIPLE SCLEROSIS A MICROGLIOPATHY?
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious mononucleosis is a more realistic target for preventing multiple sclerosis.
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, E Ann Yeh, Michael Levy

Mult Scler Relat Disord· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential mechanisms of how B-cell depletion works in MOGAD.
Philippe A Bilodeau, Ann Yeh, Jeannette Lechner-Scott, Christopher H Hawkes, Gavin Giovannoni

Mult Scler Relat Disord· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smouldering-associated worsening or SAW: the next therapeutic challenge in managing multiple sclerosis.
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open access publishing and the future of scientific communication.
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In the era of antiviral trials for MS, the answer lies in the details.
Natalia Drosu, Kjetil Bjornevik, Philippe A Bilodeau, Ann Yeh, Jeannette Lechner-Scott, Christopher H Hawkes

Mult Scler Relat Disord· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis.
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is multiple sclerosis a glymphaticopathy?
Alaa A Alghanimy, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, E Ann Yeh, Christopher H Hawkes

Mult Scler Relat Disord· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS resilience in the progression of MS.
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is using ChatGPT to help write papers and grants is useful, and ethical?
Michael Levy, Ann Yeh, Christopher Hawkes, Jennette Lechner-Scott, Gavin Giovannoni

Mult Scler Relat Disord· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond the B-cell as a treatment target in multiple sclerosis.
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Migraine and multiple sclerosis: The final answer?
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myopia in late adolescence and subsequent multiple sclerosis among men.
Ayako Hiyoshi, Christopher H Hawkes, James E Neffendorf, Tomas Olsson, Gavin Giovannoni

Mult Scler Relat Disord· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are we ready for CD19-targeted CAR T-cell therapies in MS?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer risk and mortality in multiple sclerosis: The need for vigilance.
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What are T-cells telling us about how EBV causes MS?
Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, Michael Levy, E Ann Yeh

Mult Scler Relat Disord· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biological rabbit hole: Only for the blind.
Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, Michael Levy, Ann Yeh

Mult Scler Relat Disord· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis